Description
Developer of transmembrane therapeutic peptides designed to identify peptidomimetic candidates suffering from hetero. The company develops its pipeline against key targets in the fields of oncology and immuno-oncology and is open to initiating collaboration with pharma partners on receptors of interest, enabling professionals to identify peptidomimetic candidates interfering with the hetero and/or the homodimerization of target receptors.
Contact Information
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
2. Angel (individual) | 31-Mar-2020 | $323K | 00.000 | 00.000 | Completed | Generating Revenue |
1. Seed Round | 15-Mar-2017 | 00.000 | 00.000 | 00.000 | Completed | Generating Revenue |
Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
---|---|---|---|---|---|---|---|---|
Ordinary | 0,000 | 00.000000 | 000.00 | 000.00 | 00 | 000.00 | 0.000 | |
Ordinary | 0,000 | 00.000000 | 000.00 | 000.00 | 00 | 000.00 | 0.00 | |
A shares | 7,143 | $1.107247 | $77.51 | $77.51 | 1x | $77.51 | 16.24% |
Name | Title | Board Seat | Contact Info |
---|---|---|---|
Marjorie Sidhoum Ph.D | President | ||
Gerard Cremel | Co-Founder & Founding Member | ||
Dominique Bagnard Ph.D | Co-Founder | ||
Pascal Neuville | Co-Founder |
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|---|---|---|---|---|
Capital Grand Est | PE/Buyout | Minority | 000 0000 | 000000 0 | |
Domain Therapeutics | VC-Backed Company | Minority | 000 0000 | 000000 0 |
Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
---|---|---|---|---|---|
0000 00000000 | 08-Jun-2020 | 00000 0000 | Drug Discovery | 00000000 |